-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IEOkkaIKp8BQeVBFxv3f8kj5HLHAtTBtNyYpVQMBF4yQ8aelTMjBBFrIkMgDJCMn
 6Zv4TIYQxxn34Gkdul8DCw==

<SEC-DOCUMENT>0000950134-02-010084.txt : 20020814
<SEC-HEADER>0000950134-02-010084.hdr.sgml : 20020814
<ACCEPTANCE-DATETIME>20020814160937
ACCESSION NUMBER:		0000950134-02-010084
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20020814
ITEM INFORMATION:		Financial statements and exhibits
ITEM INFORMATION:		
FILED AS OF DATE:		20020814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SHEFFIELD PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		02736643

	BUSINESS ADDRESS:	
		STREET 1:		425 WOODSMILL RD
		CITY:			ST LOUIS
		STATE:			MO
		ZIP:			63017
		BUSINESS PHONE:		3145799899

	MAIL ADDRESS:	
		STREET 1:		425 WOODSMILL RD
		CITY:			ST LOUIS
		STATE:			MO
		ZIP:			63017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c71278e8vk.txt
<DESCRIPTION>FORM 8-K
<TEXT>
<PAGE>
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): August 14, 2002

                             ----------------------

                         COMMISSION FILE NUMBER 1-12584

<TABLE>
<S>                                 <C>                                                 <C>
DELAWARE                                SHEFFIELD PHARMACEUTICALS, INC.                      13-3808303
(State of other jurisdiction of     (Exact name of registrant as specified              (I.R.S. Employer
incorporation or organization)                  in its charter)                         Identification No.)
</TABLE>

    14528 South Outer Forty Road, Suite 205, St. Louis, Missouri    63017
- --------------------------------------------------------------------------------
          (Address of principal executive officers)              (Zip Code)

        Registrant's telephone number, including area code (314) 579-9899
                             ----------------------

                                 Not Applicable
         --------------------------------------------------------------
          (Former name or former address, if changed since last report)
<PAGE>
ITEM 9. REGULATION FD DISCLOSURE

     Sheffield Pharmaceuticals, Inc. (the "Company"), a Delaware corporation, is
furnishing under Item 9 of this Current Report on Form 8-K the information
included as Exhibit 99.1 to this report. Exhibit 99.1 includes a certification
signed by the Company's Chief Executive Officer and Chief Financial Officer as
required pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, in connection with the Quarterly Report on
Form 10-Q for the period ending June 30, 2002.

Note: The information in this report (including Exhibit 99.1) is furnished under
Item 9 pursuant to 18 U.S.C. Section 1350 and shall not be deemed to be "filed"
for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section. This report
will not be deemed an admission as to the materiality of any information in the
report that is required to be disclosed solely by Regulation FD.


ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c)  Exhibits

<TABLE>
<CAPTION>
Exhibit Number             Description
<S>                        <C>
    99.1                   Certification pursuant to 18 U.S.C. Section 1350 as
                           adopted pursuant to Section 906 of the Sarbanes-Oxley
                           Act of 2002
</TABLE>


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Dated:  August 14, 2002               By: /s/ Thomas M. Fitzgerald
                                          --------------------------------------
                                      Thomas M. Fitzgerald
                                      President and Chief Executive Officer



                                      By: /s/ Scott A. Hoffmann
                                          --------------------------------------
                                      Scott A. Hoffmann
                                      Vice President and Chief Financial Officer


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>c71278exv99w1.txt
<DESCRIPTION>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
<TEXT>
<PAGE>
                                                                    EXHIBIT 99.1



           CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED
            PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Sheffield Pharmaceuticals, Inc. (the
Company") on Form 10-Q for the period ending June 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), the
undersigned Chief Executive Officer and Chief Financial Officer of the Company
hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that based on their knowledge: 1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, and 2) the information contained in the Report
fairly presents, in all material respects, the financial condition and results
of operations of the Company as of and for the periods covered in the Report.




/s/ Thomas M. Fitzgerald
- ---------------------------------------------
Thomas M. Fitzgerald, Chief Executive Officer



/s/ Scott A. Hoffmann
- ---------------------------------------------
Scott A. Hoffmann, Chief Financial Officer


August 14, 2002

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
